B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy

References

• Ratanatharathorn V, Ayash L, Lazarus HM, . Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplant 2001;28:121–129.
   PubMed Web of Science ®Google Scholar
• Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813–1826.
   PubMed Web of Science ®Google Scholar
• Karanes C, Nelson GO, Chitphakdithai P, . Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008;14:8–15.
   PubMed Web of Science ®Google Scholar
• Arora M, Wagner JE, Davies SM, . Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001;7:265–273.
   PubMed Web of Science ®Google Scholar
• Koc S, Leisenring W, Flowers ME, . Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002;100:48–51.
   PubMed Web of Science ®Google Scholar
• Goulmy E, Schipper R, Pool J, . Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281–285.
   PubMed Web of Science ®Google Scholar
• Biedermann BC, Sahner S, Gregor M, . Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002;359:2078–2083.
   PubMed Web of Science ®Google Scholar
• Socie G, Ritz J, Martin PJ. Current challenges in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010;16:S146–S151.
   PubMedGoogle Scholar
• Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215–233.
   PubMed Web of Science ®Google Scholar
• Patriarca F, Skert C, Sperotto A, . The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 2006;34:389–396.
   PubMed Web of Science ®Google Scholar
• Svegliati S, Olivieri A, Campelli N, . Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007;110:237–241.
   PubMed Web of Science ®Google Scholar
• Zhang C, Todorov I, Zhang Z, . Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006;107:2993–3001.
   PubMed Web of Science ®Google Scholar
• Miklos DB, Kim HT, Miller KH, . Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005;105:2973–2978.
   PubMed Web of Science ®Google Scholar
• Miklos DB, Kim HT, Zorn E, . Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004;103:353–359.
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Carson E, Reynolds C, . Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000;133:275–279.
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Ayash L, Reynolds C, . Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003;9:505–511.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Okano A, Akamatsu S, . Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006;20:172–173.
   PubMed Web of Science ®Google Scholar
• Mohty M, Marchetti N, El-Cheikh J, . Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008;41:909–911.
   PubMed Web of Science ®Google Scholar
• Zaja F, Bacigalupo A, Patriarca F, . Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007;40:273–277.
   PubMed Web of Science ®Google Scholar
• Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, . Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004;104: 2603–2606.
   PubMed Web of Science ®Google Scholar
• Cutler C, Miklos D, Kim HT, . Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006;108:756–762.
   PubMed Web of Science ®Google Scholar
• Teshima T, Nagafuji K, Henzan H, . Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int J Hematol 2009;90:253–260.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, . Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2009;15:1005–1013.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Lee JW, Jung CW, . Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 2010;95:1935–1942.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, . Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009;113:3865–3874.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, . Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood 2011;117:2275–2283.
   PubMed Web of Science ®Google Scholar
• Khan WN. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 2009;183:3561–3567.
   PubMed Web of Science ®Google Scholar
• Cancro MP. Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol 2009;9:657–661.
   PubMed Web of Science ®Google Scholar
• Wardemann H, Yurasov S, Schaefer A, . Predominant autoantibody production by early human B cell precursors. Science 2003;301:1374–1377.
   PubMed Web of Science ®Google Scholar
• Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989;337:562–566.
   PubMed Web of Science ®Google Scholar
• Hartley SB, Crosbie J, Brink R, . Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 1991;353:765–769.
   PubMed Web of Science ®Google Scholar
• Allman DM, Ferguson SE, Lentz VM, . Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. J Immunol 1993;151:4431–4444.
   PubMed Web of Science ®Google Scholar
• Treml JF, Hao Y, Stadanlick JE, . The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 2009;53:1–16.
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P, Rennert P, . BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231–264.
   PubMed Web of Science ®Google Scholar
• Batten M, Groom J, Cachero TG, . BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000;192:1453–1466.
   PubMed Web of Science ®Google Scholar
• Hsu BL, Harless SM, Lindsley RC, . Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002;168:5993–5996.
   PubMed Web of Science ®Google Scholar
• Lentz VM, Hayes CE, Cancro MP. Bcmd decreases the life span of B-2 but not B-1 cells in A/WySnJ mice. J Immunol 1998;160: 3743–3747.
   PubMed Web of Science ®Google Scholar
• Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997;90:1073–1083.
   PubMed Web of Science ®Google Scholar
• Kraus M, Alimzhanov MB, Rajewsky N, . Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004;117:787–800.
   PubMed Web of Science ®Google Scholar
• Lesley R, Xu Y, Kalled SL, . Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004;20:441–453.
   PubMed Web of Science ®Google Scholar
• Thien M, Phan TG, Gardam S, . Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20: 785–798.
   PubMed Web of Science ®Google Scholar
• Stadanlick JE, Kaileh M, Karnell FG, . Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat Immunol 2008;9:1379–1387.
   PubMed Web of Science ®Google Scholar
• Sen R. Control of B lymphocyte apoptosis by the transcription factor NF-kappaB. Immunity 2006;25:871–883.
   PubMed Web of Science ®Google Scholar
• Woodland RT, Fox CJ, Schmidt MR, . Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 2008;111:750–760.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, . The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009;114:4919–4927.
   PubMed Web of Science ®Google Scholar
• Corre E, Carmagnat M, Busson M, . Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections. Haematologica 2010;95:1025–1029.
   PubMed Web of Science ®Google Scholar
• Storek J, Ferrara S, Ku N, . B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant 1993;12:387–398.
   PubMed Web of Science ®Google Scholar
• Storek J, Witherspoon RP, Storb R. Reconstitution of membrane IgD- (mIgD-) B cells after marrow transplantation lags behind the reconstitution of mIgD + B cells. Blood 1997;89:350–351.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, . High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007;13:6107–6114.
   PubMed Web of Science ®Google Scholar
• Alousi AM, Uberti J, Ratanatharathorn V. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant. Leuk Lymphoma 2010;51:376–389.
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007;3:86–95.
   PubMedGoogle Scholar
• Stasi R, Cooper N, Del Poeta G, . Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008;112:1147–1150.
   PubMed Web of Science ®Google Scholar
• Roll P, Palanichamy A, Kneitz C, . Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54:2377–2386.
   PubMed Web of Science ®Google Scholar
• von Bonin M, Oelschlagel U, Radke J, . Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 2008;86:875–879.
   PubMed Web of Science ®Google Scholar